CoChat

Nanoparticulate Drug Delivery to the Retina

Li, Qingqing, Weng, Jingwen, Wong, Si Nga, Thomas Lee, Wai Yip, Chow, Shing Fung · 2021 · Molecular Pharmaceutics

The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.

Abstract

Retinal diseases, such as age-related macular degeneration and diabetic retinopathy, are the leading causes of blindness worldwide. The mainstay of treatment for these blinding diseases remains to be surgery, and the available pharmaceutical therapies on the market are limited, partially owing to various biological barriers in hindering the delivery of therapeutics to the retina. The nanoparticulate drug delivery system confers the capability for delivering therapeutics to the specific ocular targets and, hence, potentially revolutionizes the current treatment landscape of retinal diseases. While the research to date indicates the enormous therapeutics potentials of the nanoparticulate delivery systems, the successful translation of these systems from the bench to bedside is challenging and requires a combined understanding of retinal pathology, physiology of the eye, and particle and formulation designs of nanoparticles. To this end, the review begins with an overview of the most prevalent retinal diseases and related pharmacotherapy. Highlights of the current challenges encountered in ocular drug delivery for each administration route are provided, followed by critical appraisal of various nanoparticulate drug delivery systems for the retinal diseases, including their formulation designs, therapeutic merits, limitations, and future direction. It is believed that a greater understanding of the nano-biointeraction in eyes will lead to the development of more sophisticated dru…

Overview

Integrity signals

Registry

Crossref · 10.1021/acs.molpharmaceut.0c00224

Cites

153 of 153 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Research works printed but not linked: 9

  1. 10.18043/ncm.78.2.124 · DOI
  2. Moraru A. D., 2014, Rom j Morphol Embryol., 55, 869
  3. Spitznas M., 1974, Adv. Ophthalmol., 28, 78
  4. Bochot A., 2002, Invest Ophthalmol Vis Sci., 43, 253
  5. Fiscella R., 1987, Can. J. Ophthalmol., 22, 307
  6. Rahman M., 2012, Polyester
  7. 10.1016/j.jconrel.2012.12.005 · DOI · Paper page
  8. Su D. H., 2006, Invest. Ophthalmol. Vis. Sci., 47, 5122
  9. Cai X., 2016, Mol. Vis., 22, 1176

Cited by

See all 59

Metadata

Authors
Li, Q., Weng, J., Wong, S. N., Thomas Lee, W. Y., & Chow, S. F.
Affiliations
  • Xi'an Jiaotong University (CN)
  • University of Hong Kong (HK)
  • Aptorum Group Limited, Unit 232, 12 Science Park West Avenue, Hong Kong Science Park, Shatin New Town, Hong Kong
Corresponding author
Chow, Shing Fung
Venue
Molecular Pharmaceutics
Published
2020-06-08
Volume
18
Issue
2
Pages
506-521
ISSN
  • 1543-8384 (ISSN-L)
  • 1543-8392
OpenAlex
W3033428304
Cited by
59
References
153
Citations by year
2026: 8 · 2025: 11 · 2024: 11 · 2023: 12 · 2022: 9 · 2021: 8
FWCI
0.63
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Pharmaceutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • University of Hong Kong (202007002)
  • Natural Science Foundation of Shaanxi Province (2020JQ-093)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
Keywords
nanoparticle drug delivery, retinal drug delivery, ocular drug delivery, age-related macular degeneration, diabetic retinopathy, retinal disease, ocular barriers, translation to clinical practice
MeSH terms
Administration, Oral, Animals, Blindness, Blood-Retinal Barrier, Choroid, Conjunctiva, Cornea, Disease Models, Animal, Humans, Ophthalmic Solutions, Permeability, Retina, Retinal Diseases, Sclera, Nanoparticles, Administration, Ophthalmic, Administration, Intravenous, Drug Liberation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.